MedTrace Logo

18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia

NCT01916148 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-04-27

No results posted yet for this study

Summary

This purpose of this study is to determine the ability of an 18F-fluoro-L-dihydroxyphenylalanine (18F-DOPA) PET (Positron Emission Tomography) scan to detect a focal lesion of hyperinsulinism and determine the location in patients with congenital hyperinsulinism, Beckwith Wiedemann Syndrome and suspected insulinoma. Safety data will be collected.

Conditions

  • Congenital Hyperinsulinism (CHI)
  • Beckwith-Wiedemann Syndrome
  • Insulinoma

Interventions

DRUG

18F-DOPA

18F-DOPA is a PET (Positron Emission Tomography) scan radiotracer.

Sponsors & Collaborators

Principal Investigators

  • Lisa States, MD · Children's Hospital of Philadelphia

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01916148 on ClinicalTrials.gov